Oct 10th 2012 - Edison Investment Research today published a report on LeMaitre Vascular entitled "Waiting For An Inflection". In summary, the report says:
Investment summary: Waiting for an inflection LeMaitre is a leader in niche markets serving cardiovascular surgeons and has recovered well after a disastrous foray into non-core areas several years ago. Underlying sales (ex-stent grafts) have provided steady 8-9% revenue growth, but with the overall market for its products now growing 2-5%, it is unclear whether the growth rate is sustainable. New bolt-on acquisitions similar to the XenoSure biocompatible patch (c 60% sales growth a year) could help renew investor interest.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »